Ke hoʻolaha nei ʻo Priothera Ltd. i kēia lā ua hāʻawi ka US Food and Drug Administration (FDA) i ka ʻae e hoʻomau me ka noi ʻana o ka Hui Investigational New Drug (IND) e hoʻomaka i kāna haʻawina pivotal Phase 2b/3 o mocravimod (i kapa ʻia ʻo MO-TRANS).
E hoʻomaka ana ʻo Priothera i ka MO-TRANS honua Phase 2b/3 aʻo ma ʻEulopa, US a me Iapana, e loiloi ana i ka pono a me ka palekana o ka mocravimod ma ke ʻano he adjunctive a me ka mālama mālama ʻana i nā poʻe maʻi Acute Myeloid Leukemia (AML) e hana ana i ka allogenic hematopoietic stem cell transplant (HSCT). ). Manaʻo ʻia ka haʻawina MO-TRANS e hoʻomaka i ka hapa ʻelua o 2022 a manaʻo ʻia ka ʻikepili mua mai kēia noiʻi ʻana ma ka hopena o 2024.
ʻO ka hoʻololi ʻana i nā cell stem allogenic wale nō ke ala e hiki ke hoʻoponopono ʻia no nā maʻi AML, akā naʻe pili mau nā koho lapaʻau i kēia manawa me ka helu kiʻekiʻe o nā hopena ʻaoʻao, a me ka nui o ka make.
Ua ʻōlelo ʻo Florent Gros, Co-Founder a me Luna Hoʻokele o Priothera, "ʻO ka ʻae ʻana o ka FDA IND e hoʻomaka i ka noiʻi MO-TRANS e loiloi ana i ka mocravimod i nā poʻe maʻi AML e loaʻa ana i ka allogeneic HSCT kahi mea nui nui no Priothera. Aia mākou ma ke ala e hoʻomaka ai i kēia hoʻokolohua lapaʻau Phase 2b/3 a ke kakali nei mākou e hana pū me kahi hui nui o nā mea noiʻi hoihoi ma waena o US, ʻEulopa a me ʻAsia, ka mea e kaʻana like i kā mākou pahuhopu e lawe mai i ka mocravimod i nā maʻi ma ke ʻano he hoʻohui a mālama mālama. no ka AML a me nā maʻi maʻi hematologic ʻē aʻe. "